Precision Optics (POCI) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
14 May, 2026Executive summary
Achieved record Q3 revenue of $8.7 million, up 108% year-over-year and 18% sequentially, driven by core production programs and operational improvements.
Positive adjusted EBITDA reached for the first time at $0.3 million, reflecting improved manufacturing efficiency and cost controls.
Net loss narrowed to $108,000 from $2.1 million a year ago and $1.8 million in the prior quarter.
Strengthened balance sheet with an oversubscribed public offering in March 2026, raising $10–$10.6 million in net proceeds for growth initiatives.
Increased full-year fiscal 2026 revenue and adjusted EBITDA guidance based on strong results and visibility.
Financial highlights
Q3 revenue was $8.7 million, up 108% year-over-year and up from $7.4 million in the prior quarter.
Gross margin improved to 23.6% from 10% a year ago and 2.8% in the prior quarter.
Net loss per share improved to $(0.01) in Q3 from $(0.30) year-over-year.
Cash and cash equivalents at March 31, 2026, were $10.7 million, up from $900,000 at December 31, 2025, and $1.8 million at prior year-end.
Nine-month revenue was $22.8 million, up from $12.9 million year-over-year.
Outlook and guidance
Fiscal 2026 revenue guidance raised to $29–$31 million (previously $26–$28 million), representing 52%–62% growth over fiscal 2025.
Fiscal 2026 adjusted EBITDA guidance improved to -$2.5 million to -$2.7 million (previously -$2.5 million to -$3.0 million).
Q4 expected to be roughly break-even on adjusted EBITDA.
Management expects available cash, operations, and capital markets access to cover working capital and capital expenditures for at least 12 months.
Anticipates continued strong performance from lead aerospace and cystoscope lines, with new programs ramping in fiscal 2027.
Latest events from Precision Optics
- Strong revenue growth and major orders fuel expansion in medical and defense optics.POCI
Investor presentation16 Apr 2026 - Record revenue growth offset by margin compression and liquidity risks.POCI
Q2 202617 Feb 2026 - Shareholders will vote on director elections, executive pay, and auditor ratification at the 2025 meeting.POCI
Proxy Filing3 Feb 2026 - Votes will be cast on director elections, executive pay, and auditor ratification at the 2026 meeting.POCI
Proxy Filing2 Feb 2026 - Annual meeting to elect directors, approve executive pay, and ratify auditor, with strong governance.POCI
Proxy Filing2 Feb 2026 - Record engineering revenue and new orders support double-digit growth expectations for FY2025.POCI
Q4 202420 Jan 2026 - Strong product pipeline and new production ramp-ups set the stage for record growth in 2025.POCI
Lytham Partners Fall 2024 Investor Conference19 Jan 2026 - Net loss widened on lower revenue and margin, but growth is expected as new programs scale.POCI
Q1 202514 Jan 2026 - Single-use endoscopes and the Unity platform are fueling rapid growth and production expansion.POCI
Lytham Partners 2025 Industrials & Basic Materials Investor Summit26 Dec 2025